Navigation Links
AEterna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles

Second generation pyridopyrazine-urea derivative compound series show highly selective PI3K-inhibition which could be valuable for cancer treatment

QUEBEC, April 16, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global, pure play biopharmaceutical company focused on endocrine therapy and oncology, today presented an abstract outlining first in vitro data on its pyridopyrazine derivatives with high selectivity for PI3K inhibition, at the American Association for Cancer Research (AACR) Annual Meeting being held this week at the Los Angeles Convention Center in Los Angeles, California.

Results

The poster #2379 entitled, "New Generation of Anilino-Substituted Pyridopyrazine-Urea Derivatives Show Highly Selective PI3K-Inhibition", reviewed for the first time, results for a preclinical development program on a new generation of pyridopyrazine derivatives which clearly indicate that these drug candidates selectively inhibit PI3K.

Furthermore, an optimization process of our already known aryl-pyridopyrazine series led to the identification of a new lead compound in this series. A medicinal chemistry program was then initiated which resulted in the synthesis of new anilino-substituted pyridopyrazines. Out of this second generation series, several derivatives also with highly-selective PI3K inhibition as well as improved cellular efficacy and better drug-like properties, were identified.

    Conclusions


         - Novel low molecular weight kinase inhibitor

         - Excellent in vitro activity against PI3K

         - High selectivity against a panel of more than 50 kinases

         - Anti-proliferative efficacy in diverse tumor cell-lines

         - Promising bioavailability observed for lead compound

         - PI3K signalling network covers enormous therapeutic potential

"We are pleased with these results which exemplify our capability of developing novel the rapeutic approaches that add to the breadth and depth of our product pipeline," said Dr Jurgen Engel, Executive Vice President, Global R&D and Chief Operating Officer at AEterna Zentaris. "The potential for cancer treatment with agents inhibiting the PI3K pathway has become a focus in recent drug discovery and development research. We believe that by developing novel selective PI3K inhibiting small molecular compounds, we are positioning ourselves as one of the leaders in this promising therapeutic approach."

Cellular substrate phosphorylation studies targeting the inhibition of PI3K and functional cellular assays of tumor cell proliferation have been performed. In addition, physicochemical and initial ADMET data were collected. Several derivatives are currently undergoing first pharmacokinetic in vivo studies.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global, pure play biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization.

News releases and additional information are available at www.aeternazentaris.com

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "believes", "anticipates", "intends", "plans", "expects", "estimates", "will," "may", "should", "approximately", and the negative or other variations of those terms or comparable terminology, are forward-looking statements. Such statements reflect management's current views, intentions, strategies and plans and are based on certain assumptions.

Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual res ults to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the ability of AEterna Zentaris to implement its business strategies, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of AEterna Zentaris to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements.at www.aeternazentaris.com.

CONTACT: Jenene Thomas, Senior Director, Investor Relations & CorporateCommunications, (418) 655-6420, ; PaulBurroughs, Media Relations, (418) 652-8525, ext. 406, jenene.thomas@aeternazentaris.com paul.burroughs@aeternazentaris.com

Ticker Symbol: (Toronto:AEZ.),(NASDAQ-NMS:AEZS)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
2. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
3. AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
9. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
10. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
11. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Oct. 12, 2017 AVACEN Medical , Inc. ... with their  2017 New Product Innovation Award for Its ... primary and secondary medical device market research by Frost & ... first-to-market OTC, drug-free pain relief product, the AVACEN 100, offers ... treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... Oct. 11, 2017  BioPharmX Corporation (NYSE MKT: BPMX) ... developed an innovative way to use nonlinear optical imaging ... of new drugs. ... Conference will show how researchers from BioPharmX and the ... School used a suite of imaging techniques in what ...
(Date:10/11/2017)... 11, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), ... in Las Piedras, Puerto Rico , ... Following a ... sustained minor structural damage, temporary loss of power and ... been completed, manufacturing operations have resumed, and the company ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and fastest ... to open a flagship location in Covington, LA at 401 N. U.S. Highway 190, ... next to Office Depot in the Holiday Square shopping center. Its location allows it ...
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
Breaking Medicine News(10 mins):